12 terminated, 11 completed, 2 withdrawn, 1 active not recruiting. 27 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 27 | Terminated 12, Completed 11, Withdrawn 2, Active not recruiting 1, Recruiting 1 |
| Phase 1 | 4 | Terminated 3, Completed 1 |
Follow idelalisib: new trials by email Literature Review of idelalisib trials Research Report on idelalisib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis CAL101, Placebo - Idiopathic Pulmonary Fibrosis | Phase 2 | Active not recruiting | Calluna Pharma AS | 150 | 2025-06-20 | 2026-04-27 |
| Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer Alectinib, Cetuximab, Crizotinib - Metastatic Colorectal Cancer | Phase 2 | Recruiting | Oslo University Hospital | 40 | 2022-09-27 | 2023-02-21 |
| Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma Loncastuximab Tesirine, Idelalisib - Relapsed Follicular Lymphoma, Refractory Follicular Lymphoma | Phase 2 | Terminated | ADC Therapeutics S.A. | 6 | 2021-11-04 | 2023-10-23 |
| Idelalisib+Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma Idelalisib, Obinutuzumab - Follicular Lymphoma | Phase 2 | Terminated | Fondazione Italiana Linfomi - ETS | 5 | 2019-10-18 | 2024-11-21 |
| REALIB-LLA-2017: Idelalisib in Patients With Acute Lymphoblastic Leukemia Idelalisib - Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Terminated | PETHEMA Foundation | 6 | 2018-07-01 | 2021-09-05 |
| 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation Zydelig - Non Hodgkin Lymphoma, Follicular Lymphoma | Phase 2 | Completed | University of Maryland, Baltimore | 17 | 2017-10-23 | 2025-06-27 |
| Pembrolizumab + Idelalisib for Lung Cancer Study Pembrolizumab, Idelalisib - Non Small Cell Lung Cancer, Metastasis | Phase 1 / Phase 2 | Terminated | Asha Nayak | 4 | 2017-09-26 | 2024-02-28 |
| Trial of Idelalisib in Patients With Relapsed Diffuse Large B-cell Lymphoma Idelalisib - Diffuse Large B Cell Lymphoma | Phase 2 | Completed | Nordic Lymphoma Group | 36 | 2017-07-07 | 2021-10-13 |
| Efficacity of Idelalisib and Obinutuzumab in Patient With Relapsed Refractory Waldenstrom's Macroglobulinemia Obinutuzumab, Idelalisib - Waldenstrom Macroglobulinemia | Phase 2 | Completed | French Innovative Leukemia Organisation | 50 | 2017-03-07 | 2023-08-29 |
| Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Tirabrutinib, Idelalisib, Obinutuzumab - Chronic Lymphocytic Leukemia | Phase 2 | Completed | Gilead Sciences | 35 | 2016-12-13 | 2022-01-21 |
| Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi Tafasitamab, Idelalisib, Venetoclax - Leukemia, Lymphocytic, Chronic, B-Cell, Chronic Lymphocytic Leukemia | Phase 2 | Completed | MorphoSys AG | 24 | 2016-11-01 | 2021-12-20 |
| Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant Ibrutinib, Idelalisib - Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia | Phase 2 | Withdrawn | Fred Hutchinson Cancer Center | 2016-03-01 | 2017-09-27 | |
| Idelalisib for Immunoglobulin M (IgM)-Associated Primary (AL) Amyloidosis Idelalisib - Amyloidosis | Phase 2 | Terminated | John Mark Sloan | 1 | 2016-01-01 | 2017-09-21 |
| Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia GS-1101 - Waldenstrom's Macroglobulinemia | Phase 2 | Terminated | Dana-Farber Cancer Institute | 5 | 2015-10-01 | 2017-01-11 |
| Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma Idelalisib, Rituximab - Follicular Lymphoma, Small Lymphocytic Lymphoma | Phase 2 | Terminated | Gilead Sciences | 10 | 2015-09-14 | 2019-05-14 |
| Sequential Regimen of Bendamustine-Debulking Followed by CAL-101 and GA101-Induction and -Maintenance in CLL (CLL2-BCG) Bendamustine, GA101, CAL-101 - Chronic Lymphocytic Leucemia | Phase 2 | Completed | German CLL Study Group | 48 | 2015-05-28 | 2024-05-09 |
| Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas Ibrutinib, Idelalisib, Laboratory Biomarker Analysis - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia | Phase 2 | Completed | Mayo Clinic | 65 | 2015-02-19 | 2026-06-24 |
| Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion Idelalisib, Rituximab - B-cell Chronic Lymphocytic Leukemia (CLL) With 17p Deletion | Phase 2 | Terminated | Gilead Sciences | 102 | 2014-08-06 | 2018-11-19 |
| A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL Idelalisib, Ofatumumab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Completed | Dana-Farber Cancer Institute | 27 | 2014-06-01 | 2026-03-17 |
| Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies Entospletinib, Idelalisib - Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma | Phase 2 | Terminated | Gilead Sciences | 66 | 2013-06-20 | 2020-06-02 |
Showing 20 of 27. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (14) · Lymphoma, Follicular (7) · Waldenstrom Macroglobulinemia (6) · Lymphoma, Non-Hodgkin (5) · Lymphoma, B-Cell, Marginal Zone (4) · Lymphoma (2) · Lymphoma, B-Cell (2) · Lymphoma, Large B-Cell, Diffuse (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Amyloidosis (1) · Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Hodgkin Disease (1) · Idiopathic Pulmonary Fibrosis (1) · Leukemia (1)
Gilead Sciences (10) · Dana-Farber Cancer Institute (2) · ADC Therapeutics S.A. (1) · Asha Nayak (1) · Calluna Pharma AS (1) · Fondazione Italiana Linfomi - ETS (1) · Fred Hutchinson Cancer Center (1) · French Innovative Leukemia Organisation (1) · German CLL Study Group (1) · John Mark Sloan (1) · Mayo Clinic (1) · MorphoSys AG (1) · Nordic Lymphoma Group (1) · OHSU Knight Cancer Institute (1) · Oslo University Hospital (1)
United States (19) · Italy (6) · France (5) · United Kingdom (5) · Germany (4) · Poland (4) · Spain (4) · Denmark (3) · Austria (2) · Belgium (2) · Hungary (2) · Norway (2) · Romania (2) · Australia (1) · Czechia (1)
Anke Muth (1) · Jean Yared, MD (1) · Jennifer Brown, MD, PhD (1) · Jorge J. Castillo, MD (1) · Langdon Miller, MD (1) · Lyndah Dreiling, MD (1) · Marc Loriaux (1) · Mats Jerkeman (1) · Mohamed Sorror (1) · Paula Cramer, Dr. med. (1) · Pierluigi Zinzani, Prof. (1) · Tormod K Guren, MDPhD (1)
PMID 26472751, PMID 24450858, PMID 24615776, PMID 24615777, PMID 24615778, PMID 26968534, PMID 27247136, PMID 28327905, PMID 28424162, PMID 29296805, PMID 30967392, PMID 31723767, PMID 33297794, PMID 33516721, PMID 33961019, PMID 34414843, PMID 38620092, PMID 39499299, PMID 41124966
2014 (1), 2015 (1), P01CA018029 (1), P30CA015704 (1), P50CA097274 (1), R21CA159265 (1)